{"entity":{"id":"nct07447570","kind":"trial","name":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","aka":[],"tldr":"A phase 2 trial of Iparomlimab and tuvonralimab in Head and neck squamous cell carcinoma, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.","summary":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC is a phase 2 interventional study registered as NCT07447570 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with 27 participants planned, started 2025-10-15 and due to reach its primary completion in 2027-12-31. Interventions recorded: Iparomlimab and Tuvonralimab injection, Hypofractionated Radiotherapy, Chemotherapy. Conditions recorded: Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody.\n\nLinked to the drug Iparomlimab and tuvonralimab because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07447570","url":"https://clinicaltrials.gov/study/NCT07447570"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["iparomlimab-tuvonralimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07447570","phase":"2","setting":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: a Multicenter, Single-arm, Phase II Clinical Study","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","participation":[{"nct":"NCT07447570","source":"https://clinicaltrials.gov/study/NCT07447570","fetchedAt":"2026-10-07T16:55:45.930Z","studySha256":"cd7e8cce9f4ed733a4d0d4d0bec44688de538172f393a18ee33e6dcd91c8eeeb","overallStatus":"RECRUITING","lastUpdatePosted":"2026-03-03","leadSponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":27,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-10-15","startedType":"actual","enrolled":27,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07447570/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/"}]}}